18:54 , Apr 26, 2017 |  BC Week In Review  |  Financial News

Annexin begins trading

On April 19, vascular disease company Annexin Pharmaceuticals AB (SSE:ANNX) began trading on NASDAQ First North in Stockholm. Annexin Pharmaceuticals AB (SSE:ANNX), Stockholm, Sweden ...
02:16 , Apr 22, 2017 |  BioCentury  |  Finance

Sweden heating up

Following a nearly 15-year deep freeze, Stockholm has become one of the hottest European markets for biotech IPOs. The recent boom reflects a ripening of several years of investment in the early stage life sciences...
07:00 , May 26, 2014 |  BioCentury  |  Emerging Company Profile

Annexin: Attenuating vascular inflammation

Annexin Pharmaceuticals AB is developing an annexin A5 protein to help stop disease progression and prevent limb amputation in peripheral arterial occlusive disease. The protein has therapeutic benefits including anti-inflammatory, antithrombotic and anti-atherosclerotic activity. Current...